Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Short Interest Update

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 10,334,707 shares, a growth of 33.0% from the December 15th total of 7,772,345 shares. Based on an average trading volume of 1,680,832 shares, the days-to-cover ratio is currently 6.1 days. Approximately 5.3% of the shares of the company are short sold. Approximately 5.3% of the shares of the company are short sold. Based on an average trading volume of 1,680,832 shares, the days-to-cover ratio is currently 6.1 days.

Institutional Trading of Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of ZBH. Vanguard Group Inc. increased its stake in Zimmer Biomet by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock worth $2,120,751,000 after buying an additional 198,370 shares during the period. Dodge & Cox grew its stake in shares of Zimmer Biomet by 5.1% in the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after acquiring an additional 1,118,710 shares in the last quarter. Capital International Investors grew its stake in shares of Zimmer Biomet by 11.5% in the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after acquiring an additional 778,467 shares in the last quarter. American Century Companies Inc. increased its position in shares of Zimmer Biomet by 8.7% during the second quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock worth $520,752,000 after acquiring an additional 458,903 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Zimmer Biomet by 1.4% in the second quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after acquiring an additional 69,485 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Citigroup cut their price target on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research note on Thursday, December 11th. BTIG Research restated a “buy” rating and issued a $112.00 price objective on shares of Zimmer Biomet in a research report on Thursday, January 8th. UBS Group reduced their target price on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a research note on Thursday, November 6th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $100.00 price target (down previously from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $100.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $107.33.

Zimmer Biomet Price Performance

Shares of NYSE ZBH traded down $1.33 during mid-day trading on Friday, reaching $87.42. The company’s stock had a trading volume of 2,681,302 shares, compared to its average volume of 1,825,838. The stock has a 50-day moving average of $91.59 and a two-hundred day moving average of $96.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. The stock has a market capitalization of $17.32 billion, a P/E ratio of 21.64, a P/E/G ratio of 2.23 and a beta of 0.62. Zimmer Biomet has a 1-year low of $85.33 and a 1-year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter last year, the firm earned $1.74 earnings per share. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th will be issued a dividend of $0.24 per share. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.